Harnessing the Potential of Adenovirus Vectored Vaccines

Holst, Peter Johannes; Thomsen, Ann Sofia Skou

doi:10.5772/22821

Cited by 1 publication

(2 citation statements)

References 80 publications

(125 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a review by Holst and colleagues, the authors propose various mechanisms, highlighting the relative contributions that multiple cell types may have in Ag-presentation and in driving Ag-specific T-cell responses following vaccination with Ad vectors. [158] These potential virus:host cell interactions are summarised schematically in Figure 3.…”

Section: Understanding Immune Responses To Adenoviral Vectored Vaccinesmentioning

confidence: 99%

See 1 more Smart Citation

Adenoviral vectors as novel vaccines for influenza

Coughlan

Mullarkey

Gilbert

2015

Journal of Pharmacy and Pharmacology

View full text Add to dashboard Cite

Objectives Influenza is a viral respiratory disease causing seasonal epidemics, with significant annual illness and mortality. Emerging viruses can pose a major pandemic threat if they acquire the capacity for sustained human-to-human transmission. Vaccination reduces influenza-associated mortality and is critical in minimising the burden on the healthcare system. However, current vaccines are not always effective in at-risk populations and fail to induce long-lasting protective immunity against a range of viruses. Key findings The development of 'universal' influenza vaccines, which induce heterosubtypic immunity capable of reducing disease severity, limiting viral shedding or protecting against influenza subtypes with pandemic potential, has gained interest in the research community. To date, approaches have focused on inducing immune responses to conserved epitopes within the stem of haemagglutinin, targeting the ectodomain of influenza M2e or by stimulating cellular immunity to conserved internal antigens, nucleoprotein or matrix protein 1. Summary Adenoviral vectors are potent inducers of T-cell and antibody responses and have demonstrated safety in clinical applications, making them an excellent choice of vector for delivery of vaccine antigens. In order to circumvent pre-existing immunity in humans, serotypes from non-human primates have recently been investigated. We will discuss the pre-clinical development of these novel vectors and their advancement to clinical trials.

show abstract

Section: Understanding Immune Responses To Adenoviral Vectored Vaccinesmentioning

confidence: 99%

“…Tissue resident cells are transduced, process Ag and present it to local CD8+ T cells via MHC class I molecules. Schematic adapted from Bassett et al and Holst et al[157,158] Lynda Coughlan et alAdenoviral Vaccines for Influenza…”

mentioning

confidence: 99%